MK-3207

DB12424InvestigationalSmall molecule

Mk3207 has been used in trials studying the treatment of Migraine and Migraine Disorders.

Mechanism: Pharmacologically active on Calcitonin gene-related peptide type 1 receptor
Curator reviewed
Formula / weight: C₃₁H₂₉F₂N₅O₃ · 557.602 g/mol (avg)
Code names: MK 3207

Resolves to

Compound

Structure

InChIKeyAZAANWYREOQRFB-SETSBSEESA-NSMILESFC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-3207, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.